340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
oleh: Ben Tran, Nabil Adra, Jean-Pascal Machiels, Sylvie Rottey, Tanya Dorff, Lisa Horvath, Matthew Rettig, Martijn Lolkema, Karen Autio, Richard Greil, Shirley Poon, Daniel Tan, Gabor Jurida, Hosein Kouros-Mehr
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.